Addressing genetic tumor heterogeneity through computationally predictive combination therapy

Boyang Zhao, Justin R. Pritchard, Douglas A. Lauffenburger, Michael T. Hemann

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Recent tumor sequencing data suggest an urgent need to develop a methodology to directly address intratumoral heterogeneity in the design of anticancer treatment regimens. We use RNA interference to model heterogeneous tumors, and demonstrate successful validation of computational predictions for how optimized drug combinations can yield superior effects on these tumors both in vitro and in vivo. Importantly, we discover here that for many such tumors knowledge of the predominant subpopulation is insufficient for determining the best drug combination. Surprisingly, in some cases, the optimal drug combination does not include drugs that would treat any particular subpopulation most effectively, challenging straightforward intuition. We confirm examples of such a case with survival studies in a murine preclinical lymphoma model. Altogether, our approach provides new insights about design principles for combination therapy in the context of intratumoral diversity, data that should inform the development of drug regimens superior for complex tumors.

Original languageEnglish (US)
Pages (from-to)166-174
Number of pages9
JournalCancer Discovery
Volume4
Issue number2
DOIs
StatePublished - Feb 1 2014

Fingerprint

Genetic Heterogeneity
Drug Combinations
Neoplasms
Therapeutics
Intuition
RNA Interference
Pharmaceutical Preparations
Lymphoma

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Zhao, Boyang ; Pritchard, Justin R. ; Lauffenburger, Douglas A. ; Hemann, Michael T. / Addressing genetic tumor heterogeneity through computationally predictive combination therapy. In: Cancer Discovery. 2014 ; Vol. 4, No. 2. pp. 166-174.
@article{330b5771c2114d6a8b8ec544f4064223,
title = "Addressing genetic tumor heterogeneity through computationally predictive combination therapy",
abstract = "Recent tumor sequencing data suggest an urgent need to develop a methodology to directly address intratumoral heterogeneity in the design of anticancer treatment regimens. We use RNA interference to model heterogeneous tumors, and demonstrate successful validation of computational predictions for how optimized drug combinations can yield superior effects on these tumors both in vitro and in vivo. Importantly, we discover here that for many such tumors knowledge of the predominant subpopulation is insufficient for determining the best drug combination. Surprisingly, in some cases, the optimal drug combination does not include drugs that would treat any particular subpopulation most effectively, challenging straightforward intuition. We confirm examples of such a case with survival studies in a murine preclinical lymphoma model. Altogether, our approach provides new insights about design principles for combination therapy in the context of intratumoral diversity, data that should inform the development of drug regimens superior for complex tumors.",
author = "Boyang Zhao and Pritchard, {Justin R.} and Lauffenburger, {Douglas A.} and Hemann, {Michael T.}",
year = "2014",
month = "2",
day = "1",
doi = "10.1158/2159-8290.CD-13-0465",
language = "English (US)",
volume = "4",
pages = "166--174",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

Addressing genetic tumor heterogeneity through computationally predictive combination therapy. / Zhao, Boyang; Pritchard, Justin R.; Lauffenburger, Douglas A.; Hemann, Michael T.

In: Cancer Discovery, Vol. 4, No. 2, 01.02.2014, p. 166-174.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Addressing genetic tumor heterogeneity through computationally predictive combination therapy

AU - Zhao, Boyang

AU - Pritchard, Justin R.

AU - Lauffenburger, Douglas A.

AU - Hemann, Michael T.

PY - 2014/2/1

Y1 - 2014/2/1

N2 - Recent tumor sequencing data suggest an urgent need to develop a methodology to directly address intratumoral heterogeneity in the design of anticancer treatment regimens. We use RNA interference to model heterogeneous tumors, and demonstrate successful validation of computational predictions for how optimized drug combinations can yield superior effects on these tumors both in vitro and in vivo. Importantly, we discover here that for many such tumors knowledge of the predominant subpopulation is insufficient for determining the best drug combination. Surprisingly, in some cases, the optimal drug combination does not include drugs that would treat any particular subpopulation most effectively, challenging straightforward intuition. We confirm examples of such a case with survival studies in a murine preclinical lymphoma model. Altogether, our approach provides new insights about design principles for combination therapy in the context of intratumoral diversity, data that should inform the development of drug regimens superior for complex tumors.

AB - Recent tumor sequencing data suggest an urgent need to develop a methodology to directly address intratumoral heterogeneity in the design of anticancer treatment regimens. We use RNA interference to model heterogeneous tumors, and demonstrate successful validation of computational predictions for how optimized drug combinations can yield superior effects on these tumors both in vitro and in vivo. Importantly, we discover here that for many such tumors knowledge of the predominant subpopulation is insufficient for determining the best drug combination. Surprisingly, in some cases, the optimal drug combination does not include drugs that would treat any particular subpopulation most effectively, challenging straightforward intuition. We confirm examples of such a case with survival studies in a murine preclinical lymphoma model. Altogether, our approach provides new insights about design principles for combination therapy in the context of intratumoral diversity, data that should inform the development of drug regimens superior for complex tumors.

UR - http://www.scopus.com/inward/record.url?scp=84896727479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896727479&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-13-0465

DO - 10.1158/2159-8290.CD-13-0465

M3 - Article

C2 - 24318931

AN - SCOPUS:84896727479

VL - 4

SP - 166

EP - 174

JO - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 2

ER -